Remdesivir
Mechanism :
This drug inhibits RNA dependent RNA polymerase of coronavirus including SARS-CoV-2 and prevents virus replication. Replication of the viral RNA results in delayed chain termination. When Metabolism of remdesivir to remdesivir triphosphate (RDV-TP) completes and fights with natural ATP substrate for transporting into nascent RNA chains by the SARS-CoV-2 RNA-dependent RNA polymerase. This is prevented by administration of Remdesivir thus treating viral infection.
Indication :
Contraindications :
Hypersensitivity to any drug ingredient
Dosing :
For SARS COVID-19:
Indicated for pediatric patients aged ≥12 years who weigh ≥40 kg who require hospitilisation.
Day 1 loading dose: 200 mg IV infused over 1-2 hours.
Day 2 and thereafter: 100 mg IV.
Adverse Effect :
eGFR decreased, Creatinine increased, Prothrombin time increased ,ALT increased, AST increased, Nausea ,Hypersensitivity reactions ,Generalized seizure ,Rash, Decrease in hemoglobin, lymphocytes
Hepatic Dose :
Not evaluated